Hepatitis C (HCV) is a blood-borne virus that can cause significant liver damage. It is estimated that 3.5 million people in the US are infected. Some people will get rid of the virus, but the majority develop chronic disease. HCV infection is one of the leading causes for individuals to eventually need a liver transplant.
Of every 100 persons infected with HCV, approximately
Most people with HCV will remain free of symptoms while they develop chronic liver disease. The problem may not be detected for many years unless someone has had a blood test for the virus or has had an ALT test for liver function.
On October 14, 2014 the US FDA approved a new drug (Harvoni) to treat a specific strain HCV. The two active ingredients (ledipasvir/sofosbuvir) interfere with enzymes in the virus that are needed for it to replicate. The FDA has categorized this as a “breakthrough therapy” because it “may demonstrate a substantial improvement over available therapies.”
This is great news for those living with HCV, but there is a major barrier to most patients. Medical insurance often doesn’t cover this treatment and the cost can be close to $100,000. This places treatment far out of reach for most people. Worse, there might be risks of counterfeit versions of the drug on the market when a cheaper generic form is sought in other countries.
This is where Trip4Care can help. We have a relationship with one of the top hospitals in the world and can coordinate treatment for a fraction of the cost with a legitimate generic form of this drug. In general, it also only requires about a two-week stay overseas. If you would like to learn more, please contact us and we can provide you with more details.